Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
The closing price of Ekso Bionics Holdings Inc (NASDAQ: EKSO) was $8.82 for the day, down -7.45% from the previous closing price of $9.53. In other words, the price has decreased by -$7.45 from its previous closing price. On the day, 0.55 million shares were traded. EKSO stock price reached its highest trading level at $10.1 during the session, while it also had its lowest trading level at $8.52.
Ratios:
Our analysis of EKSO’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 1.09 and its Current Ratio is at 1.66. In the meantime, Its Debt-to-Equity ratio is 0.51 whereas as Long-Term Debt/Eq ratio is at 0.14.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jan 06 ’26 when Jones Jason C sold 1,320 shares for $9.25 per share. The transaction valued at 12,210 led to the insider holds 25,621 shares of the business.
Jones Jason C sold 270 shares of EKSO for $1,269 on Dec 09 ’25. The Chief Operating Officer now owns 26,941 shares after completing the transaction at $4.70 per share. On Dec 09 ’25, another insider, Wong Jerome, who serves as the Chief Financial Officer of the company, sold 1,238 shares for $4.70 each. As a result, the insider received 5,819 and left with 24,771 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, EKSO now has a Market Capitalization of 23136924 and an Enterprise Value of 25369916. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.03 while its Price-to-Book (P/B) ratio in mrq is 2.39. Its current Enterprise Value per Revenue stands at 1.72 whereas that against EBITDA is -2.663.
Stock Price History:
The Beta on a monthly basis for EKSO is 0.81, which has changed by -0.19476128 over the last 52 weeks, in comparison to a change of 0.19182634 over the same period for the S&P500. Over the past 52 weeks, EKSO has reached a high of $14.33, while it has fallen to a 52-week low of $2.73. The 50-Day Moving Average of the stock is 67.24%, while the 200-Day Moving Average is calculated to be 83.33%.
Shares Statistics:
EKSO traded an average of 2.05M shares per day over the past three months and 12089700 shares per day over the past ten days. A total of 3.39M shares are outstanding, with a floating share count of 3.13M. Insiders hold about 7.65% of the company’s shares, while institutions hold 10.56% stake in the company. Shares short for EKSO as of 1765756800 were 100272 with a Short Ratio of 0.05, compared to 1763078400 on 91956. Therefore, it implies a Short% of Shares Outstanding of 100272 and a Short% of Float of 3.8900003.
Earnings Estimates
. The current market rating for Ekso Bionics Holdings Inc (EKSO) reflects the collective analysis of 2.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.43, with high estimates of -$0.43 and low estimates of -$0.43.
Analysts are recommending an EPS of between -$0.92 and -$3.42 for the fiscal current year, implying an average EPS of -$2.17. EPS for the following year is -$0.44, with 2.0 analysts recommending between -$0.15 and -$0.72.
Revenue Estimates
It is expected that $90B in revenue will be generated in . The current quarter, according to 2 analysts. It ranges from a high estimate of $5.65M to a low estimate of $4.4M. As of . The current estimate, Ekso Bionics Holdings Inc’s year-ago sales were $5.09MFor the next quarter, 2 analysts are estimating revenue of $4.55M. There is a high estimate of $4.8M for the next quarter, whereas the lowest estimate is $4.3M.
A total of 2 analysts have provided revenue estimates for EKSO’s current fiscal year. The highest revenue estimate was $15.31M, while the lowest revenue estimate was $14.1M, resulting in an average revenue estimate of $14.71M. In the same quarter a year ago, actual revenue was $17.93MBased on 2 analysts’ estimates, the company’s revenue will be $22.74M in the next fiscal year. The high estimate is $26.1M and the low estimate is $19.38M.
